NCT05652283

Who might be able to join this trial:

• You must be willing to sign a consent form before any part of the trial begins.
• You must be a woman aged 18 or older.
• You must have been diagnosed through a tissue sample (taken by surgery or needle biopsy) with a specific type of ovarian, fallopian tube, or peritoneal cancer (high-grade serous or endometrioid type) that is at an advanced stage (Stage III or IV).
• Your tissue or blood sample must be tested to check for certain gene changes related to DNA repair (HRR or HRD status).
• You must agree to provide blood and tissue samples before, during, and after treatment for additional research, such as genetic or tumour marker studies.
• You must have at least one area of cancer that can be measured on a CT or MRI scan.
• A specialist gynaecological cancer doctor must have assessed that you are either unable to have surgery that removes all visible tumour (R0 resection), or that surgery would be too risky for you.
• The reasons surgery may not be possible include a very high body weight (BMI of 40 or above), multiple long-term health conditions, malnutrition or low protein levels, moderate to large amounts of fluid in the abdomen, or a recently diagnosed blood clot (confirm with trial site).
• Your doctors expect you to live for more than 12 weeks.
• You must have a general health score (ECOG score) of 0, 1, or 2, meaning you are able to carry out basic daily activities.
• Your blood test results must show that your bone marrow, liver, and kidneys are working well enough to meet specific levels set by the trial (confirm with trial site for exact values).
• If you could become pregnant, you must have a negative pregnancy test within one week before joining, and you must use an effective non-hormonal form of contraception (such as condoms or complete abstinence) throughout the trial.

Who may not be able to join:

• People who are directly involved in designing or running this research study.
• People who are already taking part in another clinical trial using an experimental drug at the same time.
• People receiving any other cancer treatments at the same time, including chemotherapy, radiotherapy, immunotherapy, herbal/traditional medicines, or other experimental therapies.
• People with a known allergy to Pamiparib, Surufatinib, or medicines with a similar chemical make-up.
• People who cannot swallow tablets or capsules, or who have an uncontrolled gut condition (such as severe nausea, vomiting, bowel blockage, or difficulty absorbing food) that could affect how the drugs work.
• People who have already received any cancer treatment for ovarian cancer.
• People who have previously been treated with a type of drug called a PARP inhibitor.
• People who have brain or spinal cord spread of their cancer that is causing symptoms or is not under control and requires active treatment.
• People who have had major surgery within the 3 weeks before starting the trial, or who have not yet fully recovered from a previous surgery.
• People who have had another cancer in the past 3 years, except for certain treated skin cancers, breast ductal carcinoma in situ, or cervical carcinoma in situ.
• People who have been diagnosed — now or in the past — with certain bone marrow conditions called MDS or AML.
• People with serious uncontrolled health conditions, including active serious infections (such as HIV, hepatitis B, or hepatitis C), severe heart problems or a heart attack in the last 3 months, uncontrolled seizures, uncontrolled high blood pressure, or significant immune system problems.
• People whose medical history or current health situation could interfere with the trial results or their ability to follow the trial plan.
• People who received a platelet or red blood cell transfusion within 3 days before starting the trial treatment.
• People who are pregnant, breastfeeding, or planning to become pregnant during the trial.
• People who still have unresolved significant side effects (grade 2 or above) from a previous treatment, not including hair loss, nerve pain, low lymphocyte counts, or skin colour changes.

Important: Always verify eligibility with the trial site directly before applying.